Proprotein convertase subtilisin/kexin type 9 (PCSK9)

Overview

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted serine protease of the proprotein convertase family, expressed mainly in hepatocytes and also in intestine and kidney. Its role in lipid metabolism is unusual in that it does not act by cleaving its target: after autocatalytic processing it is secreted with its prodomain still bound, blocking the catalytic site, and it regulates the low-density lipoprotein receptor (LDLR) purely by binding it. Normally LDLR delivers LDL to the endosome, releases it, and returns to the surface to work again. PCSK9 bound to the receptor prevents that release, so the whole complex is routed to the lysosome and degraded. Fewer receptors means less hepatic LDL uptake and higher circulating LDL cholesterol (LDL-C). Human genetics settled the direction of effect: gain-of-function mutations cause autosomal dominant hypercholesterolemia, while loss-of-function variants confer lifelong low LDL-C and markedly reduced cardiovascular risk in people who are otherwise healthy — which is why PCSK9 became one of the most confidently validated targets in preventive cardiology before any drug existed.

Because statins raise PCSK9 through the same SREBP-2 program by which they upregulate LDLR, blocking the protease is strongly synergistic with them and removes part of the ceiling on statin monotherapy. Inhibition is achieved clinically through monoclonal antibodies that intercept circulating PCSK9 and through small interfering RNA (siRNA) that silences its hepatic synthesis and is dosed twice yearly, with macrocyclic Peptides and CRISPR-based gene editing approaches remaining experimental. Outcome trials have confirmed that the LDL-C reduction translates into fewer cardiovascular events, and no adverse consequence of very low LDL-C has emerged, consistent with what the loss-of-function carriers predicted.

Beyond cholesterol homeostasis, PCSK9 acts on other receptors and has been implicated in vascular biology, immune modulation and oncology, including ferroptosis, antigen presentation and tumor immune evasion — placing it, alongside its established role in cardiovascular disease, at the intersection of several therapeutic domains.

Recent Publications Summary

Recent studies have continued to position PCSK9 as a major therapeutic target for LDL cholesterol lowering and cardiovascular risk reduction, while also expanding interest in its broader biologic roles. In clinical and translational work, PCSK9-targeting therapies were evaluated across multiple settings, including evolocumab in Japanese patients from the PROFICIO program, inclisiran in patients with recent acute coronary syndrome and in adolescents with heterozygous familial hypercholesterolaemia, and an inclisiran-based treatment strategy for hypercholesterolaemia 41987365Apr42132192May41616799Jan40884558Aug. A pooled analysis from the VESALIUS-CV trial also examined evolocumab for reducing first major cardiovascular events in patients without known significant atherosclerosis but with diabetes 41903215Mar. In parallel, a phase 1 trial reported laroprovstat as the first oral small-molecule PCSK9 inhibitor under investigation for hypercholesterolemia, and a discovery report described enlicitide (MK-0616), an orally active macrocyclic peptide therapeutic against PCSK9 selected for clinical progression after optimization of potency, solubility, stability, and pharmacokinetics 42137960May42201324May.

Several publications focused on PCSK9 inhibition in relation to clinical outcomes and safety. Real-world evidence from the Kyoto PCSK9 Registry found that discontinuation of PCSK9 inhibitors in patients with coronary artery disease was associated with a higher incidence of major adverse cardiovascular events, with event curves diverging about 3 years after discontinuation 42438016Jul. Another study compared incident type 2 diabetes mellitus risk among patients with hyperlipidaemia treated with PCSK9 inhibitors versus statins and other nonstatin lipid-lowering agents, while a Mendelian randomization analysis examined genetically proxied inhibition of PCSK9 alongside HMGCR and NPC1L1 in relation to diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia 42274293Jun42081017May. Proteome profiling in hypercholesterolemic patients with and without familial hypercholesterolemia treated with PCSK9 inhibitors further explored treatment-associated plasma protein changes 41906435Mar.

Beyond lipid lowering, PCSK9 was investigated in disease mechanisms and emerging therapeutic contexts. In abdominal aortic aneurysm, PCSK9 was enriched in vascular smooth muscle cells, and cell-specific overexpression promoted aortic enlargement, elastin fragmentation, collagen deposition, and MMP2/9 expression; mechanistic experiments linked PCSK9 to ferritinophagy, iron accumulation, lipid peroxidation, and ferroptosis through changes in GPX4, glutathione, ferritin heavy chain-1, and Nuclear receptor coactivator 4 (NCOA4) 42269711Jun. In oncology, a phase II study was designed to test alirocumab combined with anti-PD-1 therapy in immuno-refractory metastatic non-small cell lung cancer, based on preclinical evidence that PCSK9 can act as an immunosuppressive regulator of antigen presentation 41940540Apr. Additional work in people with HIV noted that PCSK9 inhibitors can lower LDL cholesterol substantially, while the effects on arterial inflammation, endothelial function, coronary plaque, and immune dysfunction remain under study 41771366Mar. Finally, new delivery platforms for PCSK9 gene editing were reported, including lipid nanoparticle designed for CRISPR-Cas-mediated editing of PCSK9 to durably maintain low LDL cholesterol, and an endogenous-metabolite-inspired lipid system for safe mRNA delivery and PCSK9 gene editing 42080223May42401241Jul.

What Changes, What Holds

1. PCSK9 inhibition is broadening from LDL lowering into new oral and gene-editing modalities, but the core therapeutic story remains intact
REINFORCES New agents and delivery strategies extend the established account of PCSK9 as a validated target for LDL-C reduction and cardiovascular prevention, rather than replacing it. The main change is practical: the field is moving beyond injectable biologics toward oral small molecules, optimized macrocyclic peptides, and durable editing approaches, which could improve access and adherence if they translate clinically 42137960May42201324May.

2. Stopping PCSK9 inhibitors appears to carry a delayed cardiovascular penalty, and metabolic safety questions remain unsettled
NEW DIRECTION Real-world discontinuation data add a durability-of-effect concern that the Overview does not cover: benefit may not simply pause when treatment stops, but cardiovascular risk may rise after withdrawal in patients with coronary disease 42438016Jul. The same paragraph also raises unresolved questions about diabetes risk and neuropathic outcomes with genetically proxied or pharmacologic inhibition, but these are comparative safety signals rather than changes to the LDLR mechanism 42274293Jun.

3. PCSK9 is now implicated in vascular injury, immune escape, and durable editing strategies beyond cholesterol control
NEW DIRECTION The new work expands the Overview’s pleiotropic framing by tying PCSK9 to abdominal aortic aneurysm biology through ferritinophagy and ferroptosis, which is a role not previously specified in the baseline 42269711Jun. It also strengthens the idea that PCSK9 can shape tumor immune responses, with translational implications for combining inhibition with anti-PD-1 therapy, while gene-editing delivery platforms suggest a route to long-term suppression rather than repeated dosing 41940540Apr42080223May.

Overview update candidates: PCSK9 involvement in abdominal aortic aneurysm/ferroptosis; durability concerns after PCSK9 inhibitor discontinuation; broader immune-oncology relevance.